Insilico Medicine has inked a strategic drug development partnership with Qilu Pharmaceutical Group and its affiliate, Shanghai Qilu Pharmaceutical Research Center. Under this collaboration, the two entities will work hand - in - hand to develop small - molecule inhibitors aimed at specific biological targets. Their primary focus will be on tackling cardiovascular and metabolic diseases, leveraging Insilico Medicine's Pharma.AI solution.

Insilico Medicine will take the lead in designing and refining innovative small - molecule drugs through the Pharma.AI platform. On the other hand, Qilu Pharmaceutical will assume the responsibility for the subsequent stages of drug development and commercialization. The overall value of this partnership agreement surpasses HK$931 million. This figure encompasses development and sales milestone payments, along with a portion of the subsequent net sales revenue.